AstraZeneca withdraws the authorization of the vaccine in the EU. This is confirmed by the Anglo-Swedish company itself: “Considering the quantity of vaccines available and effective for the new variants of Covid-19, the Anglo-Swedish company specifies to Adnkronos Health, there has no longer been any demand for the vaccine Vaxzevria* which consequently was no longer produced or distributed, therefore not foreseeing a future demand” for the product, “AstraZeneca has therefore decided to withdraw the marketing authorization for Vaxzevria within the EU“
The admission: “May cause rare thrombosis”
Last May 1st, in a news story released by the ‘Telegraph’ and spread across the British media, the company’s shocking admission. The AstraZeneca anti-Covid vaccine “in very rare cases can cause Tts”, the so-called ‘thrombosis syndrome with thrombocytopenia’, characterized by blood clots and low blood platelet levels, the Anglo-Swedish pharmaceutical group has admitted for the first time, as part of a class action lawsuit in the United Kingdom. “The causal mechanism” by which the vaccine can cause TTS “is not known,” the company said in legal documents filed in February. “TTS – AstraZeneca also pointed out – can occur even in the absence of administration of the vaccine. The causal link in each individual case will be tested by experts”, added the company.
Administered in 150 countries
The AstraZeneca’s Covid-19 vaccine, Covishield – recalls the ‘Independent’ – it was developed by the Anglo-Swedish giant in collaboration with the University of Oxford and produced by the Serum Institute of India. It has been widely administered in over 150 countries, including Britain and India. Some studies conducted during the pandemic had indicated an anti-Covid efficacy of 60-80% for the vaccine, but cases of thrombosis, even potentially fatal ones, were reported in some people who had received the injection.
The reports: “Deaths and serious injuries”
The citizens who filed the lawsuit in the UK class action lawsuit against AstraZeneca claim the Covishield vaccine has caused deaths and serious injuries, seeking damages of up to £100 million to compensate around 50 victims. One of the complainants reported that the vaccine caused a permanent brain injury, following a thrombotic event, which prevented him from working. While contesting the accusation, in one of the court documents filed AstraZeneca acknowledged that the vaccine can cause TTS in very rare cases. Until now, however, the pharmaceutical group had always kept the point. Even in 2023, the Independent reports, he insisted on not accepting the general statement that TTS is caused by the vaccine.
WHO confirms the adverse events
L’World Health Organization, recalls the Independent, confirmed that “after vaccination with Covishield, a very rare adverse event called thrombosis with thrombocytopenia has been reported, which involves unusual and serious blood clotting events associated with a low platelet count”. According to the Council for International Organizations of Medical Sciences, very rare side effects are defined as those reported in less than 1 case in 10,000. For the WHO, however, “in countries with ongoing Sars-CoV-2 transmission, the benefit of vaccination in protecting against Covid-19 far outweighs the risks
